Today in the morning, Pfizer has published its Q2 earnings results. Revenues of $11.8 billion reflect a 9% operational decline.

Pfizer Inc (NYSE: PFE) which is one of the companies that are making history today has announced its Q2 earnings results. While the coronavirus is still a threat to the word, Pfizer is among those businesses that are believed to be a beneficiary in this unpleasant situation. At the current moment,  Pfizer is cooperating with BioNTech SE (NASDAQ: BNTX) to develop a safe and highly effective COVID-19 vaccine. And last week, it became know that the U.S. government entered a $1.95 billion deal with the companies for their vaccine. The deal presupposes the delivery of 100 million doses initially and 500 million doses later.

Pfizer reported Q2 revenues of $11.8 billion which demonstrates a 9% operational decline. In Q2 2019, the revenues of Pfizer reached $13.2 billion. Though the impact of the financial crisis is obvious, the figures managed to beat expectations.

Earlier experts forecasted that the company would $0.67 earnings per share while Pfizer sales would reach $11.6 billion in Q2. Just to compare, Pfizer earnings per share in Q1 were $0.80, while its sales reached $12 billion.

As for PFE stock, it managed to rise by over 15.2% this month which looks quite impressive. At the same time, in July, the S&P 500 index (INDEXSP: .INX) gained really 3%. Today in the pre-marker, PFE stock is 2.13% up, at $38.34.

Business News, Editor’s Choice, Market News, News, Stocks

Julia Sakovich

Having obtained a diploma in Intercultural Communication, Julia continued her studies taking a Master’s degree in Economics and Management. Becoming captured by innovative technologies, Julia turned passionate about exploring emerging techs believing in their ability to transform all spheres of our life.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *